Diana Pietro, Lughezzani Giovanni, Saita Alberto, Uleri Alessandro, Frego Nicola, Contieri Roberto, Buffi Nicolomaria, Balzarini Luca, D'Orazio Federico, Piergiuseppe Colombo, Elefante Maria Grazia, Lazzeri Massimo, Guazzoni Giorgio, Casale Paolo, Hurle Rodolfo
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy.
Bladder Cancer. 2022 Jun 3;8(2):119-127. doi: 10.3233/BLC-211611. eCollection 2022.
MRI has been proposed as a new staging tool for bladder cancer (BC), but use is limited by its high costs and low availability. 29-MHz high-resolution micro-ultrasound (mUS) technology has been suggested as an alternative to detect BC and distinguish between muscle-invasive and non-muscle invasive BC.
The aim was to compare the diagnostic accuracy of mUS vs. magnetic resonance imaging (MRI) in differentiating NMIBC and MIBC at definitive pathological examination.
This is a prospective study of patients with a primary diagnosis of BC with either positive urine cytology (UC) or negative UC and a tumor size > 25 mm from a tertiary care high volume center. mUS, with the ExactVu system with an EV29L 29 MHz side-fire transducer, and a 3-Tesla MRI were performed before transurethral resection of bladder tumor (TURBT) in every patient before undergoing TURBT. We compared the imaging results with pathological reports.
The analyzed population consisted of 58 individuals. The reported mUS and MRI sensitivity, specificity, positive, and negative predictive values were 85.0%, 76.3%, 65.4%, and 90.6%, versus 85.0%, 50.0%, 47.2%, and 86.4%, respectively. In accuracy analysis, the AUC for mUS and MRI were respectively 0.807 and 0.675.
In our population mUS seems to have a better performance in distinguishing NMIBC from MIBC. The main limitation of mUS is the probe shape that makes its use problematic in cases with a large prostate and inadequate rectal preparation. Further studies with a larger population are ongoing to compare and validate these techniques in this setting.
磁共振成像(MRI)已被提议作为膀胱癌(BC)的一种新的分期工具,但因其成本高和可用性低而使用受限。29兆赫高分辨率微超声(mUS)技术被认为是检测BC并区分肌层浸润性和非肌层浸润性BC的一种替代方法。
目的是比较mUS与磁共振成像(MRI)在最终病理检查中鉴别非肌层浸润性膀胱癌(NMIBC)和肌层浸润性膀胱癌(MIBC)的诊断准确性。
这是一项对来自三级医疗高容量中心的原发性BC患者进行的前瞻性研究,这些患者尿液细胞学检查(UC)呈阳性或阴性,且肿瘤大小>25毫米。在每位患者进行经尿道膀胱肿瘤切除术(TURBT)之前,使用配备EV29L 29兆赫侧射探头的ExactVu系统进行mUS检查,并进行3特斯拉MRI检查。我们将成像结果与病理报告进行了比较。
分析的人群包括58人。报告的mUS和MRI的敏感性、特异性、阳性和阴性预测值分别为85.0%、76.3%、65.4%和90.6%,而MRI分别为85.0%、50.0%、47.2%和86.4%。在准确性分析中,mUS和MRI的曲线下面积(AUC)分别为0.807和0.675。
在我们的研究人群中,mUS在区分NMIBC和MIBC方面似乎具有更好的性能。mUS的主要局限性在于探头形状,这使得在前列腺肿大和直肠准备不足的情况下使用存在问题。正在进行更大规模人群的进一步研究,以在这种情况下比较和验证这些技术。